Related Experiment Video
Updated: Jul 19, 2026
07:43
Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
Published on: January 17, 2018
Dopaminergic resistant prolactinomas in the peripubertal population
Carol Huang1, Shereen Ezzat, Sylvia L Asa
1Department of Pediatrics, Division of Endocrinology, Hospital for Sick Children and University of Toronto, Ontario, Canada.
Journal of Pediatric Endocrinology & Metabolism : JPEM
|September 26, 2006
Summary
Two children with resistant hyperprolactinemia and macroadenomas required surgery due to secondary pituitary dysfunction. Growth hormone treatment did not increase tumor size in one patient, suggesting potential therapeutic avenues.
Area of Science:
- Pediatric Endocrinology
- Neurosurgery
Background:
- Macroadenomas can cause hyperprolactinemia, leading to pituitary dysfunction.
- Dopamine agonists are the primary medical treatment for hyperprolactinemia.
Observation:
- Two pediatric patients presented with macroadenomas and hyperprolactinemia resistant to dopamine agonist therapy.
- Secondary pituitary dysfunction developed in both patients.
Findings:
- Surgical debulking was necessary for both patients.
- One patient received growth hormone treatment, with no observed increase in tumor size.
Implications:
- Highlights the need for surgical intervention in select cases of resistant pituitary macroadenomas.
- Suggests growth hormone therapy may be safely administered post-surgery without exacerbating tumor growth.
Related Concept Videos
01:27Hormones of the Pituitary Gland
The small, pea-sized pituitary gland is located at the base of the brain. It is crucial in regulating various bodily functions, from growth to reproduction. The gland is divided into the anterior lobe and the posterior lobe. The secretory cell clusters in the pars distalis of the anterior pituitary lobe are controlled by hypothalamic regulators and synthesize six primary hormones.
The most abundantly secreted hormone from the anterior lobe is the growth hormone, which controls overall growth by...
The most abundantly secreted hormone from the anterior lobe is the growth hormone, which controls overall growth by...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
01:27Signs of Puberty
Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...